{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:12:53Z","timestamp":1783944773528,"version":"3.55.0"},"reference-count":60,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"unspecified","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020264","name":"Anne and Don Fizer Foundation","doi-asserted-by":"publisher","award":["EIN: 76-0599693"],"award-info":[{"award-number":["EIN: 76-0599693"]}],"id":[{"id":"10.13039\/100020264","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,6,24]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Bipolar II disorder (BD-II) is characterised by hypomanic and depressive episodes with the latter tending to dominate the clinical course of the disorder, and they are often associated with suicidality. Despite available guideline-based recommendations for first-line pharmacological treatments, patient outcomes remain suboptimal, especially for those with chronic depression and suicidal ideation. The dearth of viable treatment options for this population is evident, which is where psychedelics propose an additional alternative path. Psilocybin has recently shown promise in treating major depressive disorder and treatment-resistant depression; however, individuals with bipolar disorder or suicidality are typically excluded from such trials due to safety concerns (ie, risk of emerging suicidal behaviour, psychosis and\/or mania). Here, we present the protocol of a study which aims to explore the acceptability, safety and treatment preferences of psilocybin-assisted therapy in patients with BD-II struggling with suicidal ideation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This outpatient, single-site, phase II, single-arm, open-label clinical trial feasibility study will include 10 participants diagnosed with BD-II depression and moderately passive suicidal ideation. Participants may receive up to two oral doses of 25\u2009mg psilocybin, approximately 4\u2009weeks apart, alongside a structured therapeutic protocol (based on mindfulness cognitive\u2013behavioural therapy) that includes preparatory therapy sessions, psychological support during administration and post-treatment integration therapy sessions. The purpose is to examine the acceptability and safety of using psilocybin as a therapeutic for mild to moderate suicidality in patients currently diagnosed with BD-II and to obtain preliminary data on its effects. This will be measured using the following: Primary outcomes include change in suicidality, that is, the Interpersonal Needs Questionnaire and the Columbia Suicide Severity Rating Scale from baseline to main endpoint (3 weeks post initial administration) and feasibility and acceptability (as assessed by number of participants who complete the trial, number of therapy sessions attended and number of assessments completed). Secondary outcomes include changes in the following associated measures: Montgomery-Asberg Depression Rating Scale, Quick Inventory of Depressive Symptomatology, Young Mania Rating Scale, Brief Psychiatric Rating Scale Positive Symptom Subscale, Altman Self-Rating Mania Scale. Findings will also be used to estimate effect sizes and inform the design of a future randomised controlled trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval has been obtained from the UTHealth Committee for the Protection of Human Subjects (CPHS RB# HSC-MS-23-0905). The results of the study will be disseminated to the public (ie, clinicians, researchers, patients and policymakers) through peer-reviewed journals, conferences and scientific meetings and clinical registries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06706232\">NCT06706232<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-118471","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:40:34Z","timestamp":1783942834000},"page":"e118471","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Acceptability and safety of two sequential doses of psilocybin in bipolar II depression: protocol for an open-label single-arm feasibility study"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct06706232","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06706232","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4236-7778","authenticated-orcid":false,"given":"Thomas D","family":"Meyer","sequence":"first","affiliation":[{"name":"Louis A. Faillace, MD, Department of Psychiatry & Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8111-6299","authenticated-orcid":false,"given":"Lauren N","family":"Vale","sequence":"additional","affiliation":[{"name":"Louis A. Faillace, MD, Department of Psychiatry & Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4240-747X","authenticated-orcid":false,"given":"Maya","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Louis A. Faillace, MD, Department of Psychiatry & Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas, USA"},{"name":"Department of Psychology, Florida State University, Tallahassee, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4250-8078","authenticated-orcid":false,"given":"Carolina","family":"Olmos","sequence":"additional","affiliation":[{"name":"Louis A. Faillace, MD, Department of Psychiatry & Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3114-6611","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Quevedo","sequence":"additional","affiliation":[{"name":"Louis A. Faillace, MD, Department of Psychiatry & Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas, USA"},{"name":"Center for Interventional Psychiatry, Louis A. Faillace, MD, Department of Psychiatry & Behavioral Sciences, The University of Texas Health Science Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jair C","family":"Soares","sequence":"additional","affiliation":[{"name":"Louis A. Faillace, MD, Department of Psychiatry & Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"2026071304402257000_16.7.e118471.1","unstructured":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th edn. Arlington, VA, US: American Psychiatric Publishing, Inc, 2013."},{"key":"2026071304402257000_16.7.e118471.2","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-021-01500-w","article-title":"Assessment of suicide attempt and death in bipolar affective disorder: a combined clinical and genetic approach","volume":"11","author":"Monson","year":"2021","journal-title":"Transl Psychiatry"},{"key":"2026071304402257000_16.7.e118471.3","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1080\/03007995.2019.1636017","article-title":"Bipolar depression: the clinical characteristics and unmet needs of a complex disorder","volume":"35","author":"McIntyre","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"2026071304402257000_16.7.e118471.4","doi-asserted-by":"crossref","DOI":"10.1017\/S2045796019000593","article-title":"Prevalence of suicide attempts in bipolar disorder: a systematic review and meta-analysis of observational studies","volume":"29","author":"Dong","year":"2020","journal-title":"Epidemiol Psychiatr Sci"},{"key":"2026071304402257000_16.7.e118471.5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S2215-0366(16)00082-1","article-title":"NICE guidance on psychological treatments for bipolar disorder","volume":"3","author":"Kendall","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"2026071304402257000_16.7.e118471.6","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12609"},{"key":"2026071304402257000_16.7.e118471.7","unstructured":"DGBS e. V . Epidemiologie, \u00e4tiopathogenese, prognose und pr\u00e4vention. In: S3-Leitlinie zur Diagnostik und Therapie Bipolarer St\u00f6rungen. 2020."},{"key":"2026071304402257000_16.7.e118471.8","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291711002522"},{"key":"2026071304402257000_16.7.e118471.9","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.16m11027","article-title":"Psychotherapy Alone and Combined With Medication as Treatments for Bipolar II Depression: A Randomized Controlled Trial","volume":"79","author":"Swartz","year":"2018","journal-title":"J Clin Psychiatry"},{"key":"2026071304402257000_16.7.e118471.10","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1017\/S1352465819000080","article-title":"Predictors of depression relapse and recurrence after cognitive behavioural therapy: a systematic review and meta-analysis","volume":"47","author":"Wojnarowski","year":"2019","journal-title":"Behav Cogn Psychother"},{"key":"2026071304402257000_16.7.e118471.11","doi-asserted-by":"crossref","DOI":"10.1017\/S0033291725000157","article-title":"Psychological interventions for preventing relapse in individuals with partial remission of depression: a systematic review and individual participant data meta-analysis","volume":"55","author":"G\u00fclpen","year":"2025","journal-title":"Psychol Med"},{"key":"2026071304402257000_16.7.e118471.12","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116636545"},{"key":"2026071304402257000_16.7.e118471.13","doi-asserted-by":"crossref","DOI":"10.1186\/s40345-022-00265-5","article-title":"Psychedelics in the treatment of unipolar and bipolar depression","volume":"10","author":"Bosch","year":"2022","journal-title":"Int J Bipolar Disord"},{"key":"2026071304402257000_16.7.e118471.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.03.020"},{"key":"2026071304402257000_16.7.e118471.15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"2026071304402257000_16.7.e118471.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206443"},{"key":"2026071304402257000_16.7.e118471.17","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.medj.2024.01.005","article-title":"Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin","volume":"5","author":"Rosenblat","year":"2024","journal-title":"Med"},{"key":"2026071304402257000_16.7.e118471.18","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1177\/1745691619895047","article-title":"Mystical and Other Alterations in Sense of Self: An Expanded Framework for Studying Nonordinary Experiences","volume":"15","author":"Taves","year":"2020","journal-title":"Perspect Psychol Sci"},{"key":"2026071304402257000_16.7.e118471.19","unstructured":"Aaronson S , et al . An open label study of comp360 (synthetic psilocybin) in bipolar type ii depression. Presented at the American College of Neuropsychopharmacology 1st Annual Meeting, Phoenix, Arizona; 2022"},{"key":"2026071304402257000_16.7.e118471.20","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamapsychiatry.2023.4685","article-title":"Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial","volume":"81","author":"Aaronson","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"2026071304402257000_16.7.e118471.21","doi-asserted-by":"crossref","first-page":"100240","DOI":"10.1016\/j.jadr.2021.100240","article-title":"Evaluating the risk of psilocybin for the treatment of bipolar depression: A review of the research literature and published case studies","volume":"6","author":"Gard","year":"2021","journal-title":"Journal of Affective Disorders Reports"},{"key":"2026071304402257000_16.7.e118471.22","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamapsychiatry.2023.4685","article-title":"Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes","volume":"81","author":"Aaronson","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"2026071304402257000_16.7.e118471.23","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/bdi.13095","article-title":"An episode of mania following self-reported ingestion of psilocybin mushrooms in a woman previously not diagnosed with bipolar disorder: A case report","volume":"23","author":"Hendin","year":"2021","journal-title":"Bipolar Disord"},{"key":"2026071304402257000_16.7.e118471.24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0279073","article-title":"\u201cA sense of the bigger picture:\u201d A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use","volume":"17","author":"DellaCrosse","year":"2022","journal-title":"PLoS One"},{"key":"2026071304402257000_16.7.e118471.25","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamapsychiatry.2024.2546","article-title":"Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis","volume":"81","author":"Hinkle","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"2026071304402257000_16.7.e118471.26","doi-asserted-by":"publisher","DOI":"10.1177\/02698811221131997"},{"key":"2026071304402257000_16.7.e118471.27","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jad.2024.12.044","article-title":"Psychedelic use and bipolar disorder - An investigation of recreational use and its impact on mental health","volume":"373","author":"Meyer","year":"2025","journal-title":"J Affect Disord"},{"key":"2026071304402257000_16.7.e118471.28","doi-asserted-by":"crossref","unstructured":"Davis AK , Averill LA , Sepeda ND , et al . Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans. Chronic Stress 2020;4. doi:10.1177\/2470547020939564","DOI":"10.1177\/2470547020939564"},{"key":"2026071304402257000_16.7.e118471.29","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"2026071304402257000_16.7.e118471.30","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"2026071304402257000_16.7.e118471.31","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3390\/ph14121213","article-title":"Psilocybin, a Naturally Occurring Indoleamine Compound, Could Be Useful to Prevent Suicidal Behaviors","volume":"14","author":"Strumila","year":"2021","journal-title":"Pharmaceuticals"},{"key":"2026071304402257000_16.7.e118471.32","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.148.5.599"},{"key":"2026071304402257000_16.7.e118471.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.08.022"},{"key":"2026071304402257000_16.7.e118471.34","unstructured":"Joiner T . Why People Die by Suicide. Harvard University Press, 2005."},{"key":"2026071304402257000_16.7.e118471.35","doi-asserted-by":"publisher","DOI":"10.1037\/a0025358"},{"key":"2026071304402257000_16.7.e118471.36","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1027\/0227-5910\/a000898","article-title":"Clinically Significant Scores for Thwarted Belonging and Perceived Burden from the Interpersonal Needs Questionnaire (INQ-15)","volume":"44","author":"Silva","year":"2023","journal-title":"Crisis"},{"key":"2026071304402257000_16.7.e118471.37","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116678781"},{"key":"2026071304402257000_16.7.e118471.38","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115609019"},{"key":"2026071304402257000_16.7.e118471.39","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119855974"},{"key":"2026071304402257000_16.7.e118471.40","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-2007-979351","article-title":"The standardized psychometric assessment of altered states of consciousness (ASCs) in humans","volume":"31 Suppl 2","author":"Dittrich","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"2026071304402257000_16.7.e118471.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.beth.2011.03.007"},{"key":"2026071304402257000_16.7.e118471.42","doi-asserted-by":"publisher","DOI":"10.1037\/pspp0000096S"},{"key":"2026071304402257000_16.7.e118471.43","doi-asserted-by":"crossref","unstructured":"Ko K , Knight G , Rucker JJ , et al . Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review. Front Psychiatry 2022;13. doi:10.3389\/fpsyt.2022.917199","DOI":"10.3389\/fpsyt.2022.917199"},{"key":"2026071304402257000_16.7.e118471.44","doi-asserted-by":"publisher","DOI":"10.5498\/wjp.v12.i9.1204"},{"key":"2026071304402257000_16.7.e118471.45","doi-asserted-by":"publisher","DOI":"10.1177\/1073191116638410"},{"key":"2026071304402257000_16.7.e118471.46","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jpsychires.2015.04.014","article-title":"Predictors of switch from depression to mania in bipolar disorder","volume":"66\u201367","author":"Niitsu","year":"2015","journal-title":"J Psychiatr Res"},{"key":"2026071304402257000_16.7.e118471.47","doi-asserted-by":"crossref","unstructured":"Oliva V , De Prisco M , La Spina E , et al . Switch to mania after acute antidepressant treatment for bipolar depression: a systematic review and network meta-analysis of randomised controlled trials. EClinicalMedicine 2025;87. doi:10.1016\/j.eclinm.2025.103413","DOI":"10.1016\/j.eclinm.2025.103413"},{"key":"2026071304402257000_16.7.e118471.48","unstructured":"Sapra A , Malik A , Bhandari P . Vital Sign Assessment. StatPearls [internet]: StatPearls Publishing, 2023."},{"key":"2026071304402257000_16.7.e118471.49","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/cpp.320","article-title":"The mindfulness\u2010based cognitive therapy adherence scale: inter\u2010rater reliability, adherence to protocol and treatment distinctiveness","volume":"9","author":"Segal","year":"2002","journal-title":"Clin Psychology and Psychoth"},{"key":"2026071304402257000_16.7.e118471.50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2011.00236.x"},{"key":"2026071304402257000_16.7.e118471.51","unstructured":"Beck AT . Cognitive Therapy and the Emotional Disorders. Oxford, England: International Universities Press, 1976."},{"key":"2026071304402257000_16.7.e118471.52","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116662634"},{"key":"2026071304402257000_16.7.e118471.53","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jama.2025.13481","article-title":"Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial","volume":"334","author":"Robison","year":"2025","journal-title":"JAMA"},{"key":"2026071304402257000_16.7.e118471.54","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/02698811211044688","article-title":"Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis","volume":"36","author":"Leger","year":"2022","journal-title":"J Psychopharmacol"},{"key":"2026071304402257000_16.7.e118471.55","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1089\/psymed.2023.0007","article-title":"A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions","volume":"1","author":"Brennan","year":"2023","journal-title":"Psychedelic Med (New Rochelle)"},{"key":"2026071304402257000_16.7.e118471.56","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.54843","article-title":"Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis","volume":"9","author":"Florineth","year":"2026","journal-title":"JAMA Netw Open"},{"key":"2026071304402257000_16.7.e118471.57","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.genhosppsych.2025.12.021","article-title":"Psychological support can be distinguished from psychotherapy: Clarifications for future empirical work","volume":"99","author":"Schettino","year":"2026","journal-title":"Gen Hosp Psychiatry"},{"key":"2026071304402257000_16.7.e118471.58","doi-asserted-by":"publisher","DOI":"10.2466\/pr0.1962.10.3.799"},{"key":"2026071304402257000_16.7.e118471.59","doi-asserted-by":"crossref","unstructured":"Posner K , Brent D , Lucas C , et al . Columbia-Suicide Severity Rating Scale (C-SSRS). New York, NY: Columbia University Medical Center, 2008.","DOI":"10.1037\/t52667-000"},{"key":"2026071304402257000_16.7.e118471.60","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1991.01810330031005"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-118471","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:40:39Z","timestamp":1783942839000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-118471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":60,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,13]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjopen-2026-118471"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-118471","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}